AC Immune SA (ACIU) Analysts See $-0.09 EPS

February 26, 2018 - By Vivian Park

 AC Immune SA (ACIU) Analysts See $ 0.09 EPS

Analysts expect AC Immune SA (NASDAQ:ACIU) to report $-0.09 EPS on March, 16.After having $-0.16 EPS previously, AC Immune SA’s analysts see -43.75 % EPS growth. The stock increased 0.74% or $0.08 during the last trading session, reaching $10.9. About 40,353 shares traded. AC Immune SA (NASDAQ:ACIU) has 0.00% since February 26, 2017 and is . It has underperformed by 16.70% the S&P500.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has market cap of $620.45 million. The Company’s SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as Alzheimer's , Parkinson's, down syndrome, and glaucoma diseases. It currently has negative earnings. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies.

More notable recent AC Immune SA (NASDAQ:ACIU) news were published by: which released: “AC Immune files for US IPO to develop Alzheimer’s drug” on May 31, 2016, also with their article: “AC Immune IPO Has Potential But Proceed With Caution” published on September 14, 2016, published: “AC Immune to Participate in Two Investor Conferences and Provide Scientific …” on February 06, 2018. More interesting news about AC Immune SA (NASDAQ:ACIU) were released by: and their article: “AC IMMUNE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS” published on August 09, 2017 as well as‘s news article titled: “AC Immune: A Compelling Speculative Investment” with publication date: July 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.